Induced Pluripotent Stem Cell Models Transform Cystic Fibrosis Drug Discovery

Study Background and Research Question

Cystic fibrosis (CF) is a lethal, multisystem disorder caused by mutations in the CFTR gene, which encodes an anion channel essential for airway surface fluid homeostasis. Over 2,000 CFTR variants have been described, with several hundred linked to clinical disease, each causing distinct molecular defects—ranging from impaired protein synthesis to defective channel gating and conductance (paper). While the advent of CFTR modulators has brought substantial clinical benefit to approximately 90% of patients, individuals with rare or class 1 mutations remain without targeted therapies, highlighting a critical therapeutic gap (source: paper). Established preclinical models, particularly primary human bronchial epithelial cells (HBECs), have been instrumental in modulator discovery but face limitations in scalability and representation of rare genotypes. The study by Berical et al. addresses whether a scalable, patient-specific iPSC-based airway epithelial model can recapitulate CFTR dysfunction and drug response, and thus accelerate the development of therapies for underrepresented CFTR variants.

Key Innovation from the Reference Study

The primary innovation is the creation of a multimodal iPSC-derived airway epithelial cell platform encompassing a spectrum of common and rare CFTR mutations. This platform uniquely adapts both three-dimensional (3D) spheroid swelling assays and planar, polarized epithelial cultures for functional CFTR assessment in iPSC-derived cells. This dual-mode system enables genotype-to-phenotype mapping and direct evaluation of therapeutic responses in a patient-specific context (paper).

Methods and Experimental Design Insights

Berical et al. established iPSC lines from patients with representative CFTR mutations spanning three mechanistic classes. Differentiation protocols generated airway epithelial cells capable of forming either 3D spheroids or planar mucociliary layers. Two robust assay modalities were adapted:

• 3D Spheroid Swelling Assay: Spheroids were exposed to forskolin, a cAMP agonist that activates CFTR-mediated ion transport, resulting in measurable swelling in functional cells. This assay is a readout for CFTR activity based on the movement of fluid into the spheroid lumen.
• Planar ALI Cultures: iPSC-derived cells were differentiated at an air-liquid interface to establish a pseudostratified mucociliary epithelium, akin to primary HBECs. Electrophysiological studies assessed CFTR-dependent transepithelial ion currents, paralleling established protocols in primary cell models.

Importantly, the study compared baseline function and modulator response (e.g., to approved CFTR correctors and potentiators) across genotypes, leveraging both morphological and electrophysiological endpoints (paper).

Protocol Parameters

• assay | Forskolin-induced 3D spheroid swelling | typical range: 5–20 µM forskolin | applicable to iPSC-derived airway spheroids for CFTR activity readout; concentration optimized for maximal cAMP activation without off-target effects | reference_paper
• assay | Air-liquid interface (ALI) culture duration | 21–28 days | allows full mucociliary differentiation of airway epithelia from iPSCs | necessary for physiologically relevant electrophysiology | reference_paper
• assay | Electrophysiological measurement (short-circuit current) | 0.1–10 µA/cm² (response window) | measures CFTR-mediated ion transport in differentiated planar cultures | distinguishes genotype-specific and modulator-induced differences | reference_paper
• assay | Resazurin sodium salt-based metabolic viability assay | 10–50 µM (workflow recommendation) | applicable to monitor cell viability/metabolic activity in iPSC-derived airway cells, especially during drug screening or cytotoxicity assessment | avoids high concentrations/prolonged exposure to prevent underestimation of viability (product_spec)

Core Findings and Why They Matter

The iPSC-derived airway models successfully recapitulated genotype-dependent differences in CFTR function at baseline and under pharmacological modulation, as measured by both spheroid swelling and electrophysiological endpoints. Notably, the system discerned differential responses to CFTR modulators among common and rare variants, mirroring clinical heterogeneity (paper). This validates the model as a high-fidelity preclinical tool for both mechanistic studies and personalized drug testing. The ability to scale iPSC-derived models enables broader representation of rare genotypes and supports drug discovery workflows that require large numbers of functional airway epithelial cells. This is particularly important for rare CFTR variants that are underrepresented in primary cell biobanks or are not amenable to direct patient sampling.

Comparison with Existing Internal Articles

Recent literature has emphasized the growing role of advanced fluorogenic oxidation-reduction indicators, such as Resazurin sodium salt, in cell viability and drug response assays. For instance, the article "Beyond the Assay: Resazurin Sodium Salt as a Strategic Enabler" discusses the mechanistic advantages of resazurin-based viability measurements for evaluating metabolic activity and cytotoxicity in translational research, including fibrotic and oncologic disease models (internal_article). Similarly, "Resazurin Sodium Salt: Redefining Cell-Based Assays for Translational Discovery" contextualizes the use of resazurin in iPSC-based disease modeling, highlighting its sensitivity and compatibility with high-throughput screening (internal_article). The current reference study complements these perspectives by demonstrating that robust, scalable iPSC-derived platforms can integrate metabolic viability assays (such as those based on Resazurin sodium salt) to support multiparametric preclinical drug testing, particularly in complex genetic disease contexts like CF.

Limitations and Transferability

While the iPSC platform advances disease modeling fidelity and scalability, it is not without limitations. The differentiation protocols, though reproducible, can yield variable cellular composition and maturity, potentially introducing assay variability. Not all aspects of primary airway epithelial physiology may be fully recapitulated in iPSC-derived cultures. In addition, while 3D and planar assays offer complementary insights, they may not capture all dimensions of in vivo lung architecture or immune interactions. Thus, while highly informative for preclinical drug screening and mechanistic studies, findings from these models require downstream validation in primary human tissues and, ultimately, clinical trials (paper).

Research Support Resources

To implement similar workflows, researchers can incorporate robust viability and cytotoxicity assays using reagents such as Resazurin sodium salt (SKU B6098), a widely validated fluorogenic oxidation-reduction indicator for metabolic activity assessment in cell-based platforms. This reagent is suitable for high-throughput screening, flow cytometry viability applications, and fluorescence microscopy cell viability assays. As outlined in product specifications and supported by workflow recommendations, freshly prepared solutions and appropriate concentrations (typically 10–50 µM) are advised to maintain accuracy and avoid under- or overestimation of cellular viability during extended assays (product_spec).